Russell Investments Group
PRLD icon

Russell Investments Group’s Prelude Therapeutics PRLD Stock Holding History

Russell Investments Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-76
Closed -$157 – 3771
2024
Q3 		$157 Sell
76
-1,405
-95% -$6.51K ﹤0.01% 3656
2024
Q2 		$5.64K Buy
+1,481
New +$6.03K ﹤0.01% 3188

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group's PRLD Position: Q4 2024 in Review

Russell Investments Group sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 76 shares — an estimated $157 sold.

Russell Investments Group first reported a position in PRLD in Q2 2024 and held it in 2 quarters. The position peaked at $5.64K in Q2 2024. 62 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

  • Russell Investments Group reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Russell Investments Group sold 76 Prelude Therapeutics shares in Q4 2024, an estimated $157.
  • Russell Investments Group first reported a position in Prelude Therapeutics in Q2 2024 and held it in 2 quarters.
  • Russell Investments Group's Prelude Therapeutics position peaked at $5.64K in Q2 2024.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Russell Investments Group's 13F filing for Q4 2024, filed 13 Feb 2025.